Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers

[Display omitted] Using salmeterol xinafoate (SX) as an active pharmaceutical ingredient, the effects of carrier lactose particle type, total lactose fines content and device resistance on dry powder inhaler performance were investigated in vitro. To mimic drug levels in commercial preparations, int...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of pharmaceutics 2015-07, Vol.490 (1-2), p.360-367
Hauptverfasser:	Hassoun, Mireille, Ho, Shirlene, Muddle, Joanna, Buttini, Francesca, Parry, Mark, Hammond, Mark, Forbes, Ben
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Aerolizer Aerosols - chemistry Chemistry, Pharmaceutical - instrumentation Chemistry, Pharmaceutical - methods Drug Carriers - chemistry Dry powder inhaler Dry Powder Inhalers - instrumentation Equipment Design - instrumentation Handihaler Lactose Lactose - chemistry Orally inhaled product (OIP) Particle Size Powders - chemistry Rotahaler Salmeterol xinafoate (SX) Salmeterol Xinafoate - chemistry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!